Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.
Precision BioSciences To Host Webcast, Conference Call On Saturday, Dec. 11, 2021 To Review Interim Phase 1/2a Data For Its CAR-T Cell Candidate
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will
Precision BioSciences To Present Preclinical Gene Editing Data On Its ARCUS-Based Chronic Hepatitis B Program At The HEP DART 2021 Conference
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, today announced it will
12 Health Care Stocks Moving In Thursday’s After-Market Session
Gainers
NeuroOne Medical Tech (NASDAQ:NMTC) stock moved upwards by 6.47% to $2.63 during Thursday's after-market session. The company's market cap stands at $41.4 million.
Earnings Scheduled For November 10, 2021
Companies Reporting Before The Bell
• LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.
Precision BioSciences Earnings Preview
Precision BioSciences (NASDAQ:DTIL) is set to give its latest quarterly earnings report on Wednesday, 2021-11-10. Here's what investors need to know before the announcement.
Analysts estimate that Precision BioSciences will likely report an Earnings Per Share (EPS) of $-0.59
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data From Lead PBCAR0191 CAR T Immunotherapy For Relapsed And Refractory B-cell Malignancies At The 63rd Annual Meeting Of The American Society Of Hematology
- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines of Therapy
-